Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.45 |
| ▸ | NPY4R | P50391 | 16/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.45 |
| ▸ | NPY1R | P25929 | 9/20 | 0.45 |
| ▸ | NPY2R | P49146 | 7/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17349979 | 0.99 | NPY4R (0.46) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL17349855 | 0.99 | NPY4R (0.46) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL20799372 | 0.91 | NPY4R (0.46) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL19441727 | 0.90 | NPY4R (0.49) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL19441729 | 0.89 | NPY4R (0.38) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL20799368 | 0.85 | NPY4R (0.46) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL19696558 | 0.85 | NPY4R (0.55) | NPY4RNPY5RNPY1RNPY2RTLR2 | |
| SCHEMBL20724927 | 0.84 | NPY4R (0.46) | SIRT5NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL17849817 | 0.83 | NPY4R (0.47) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16421616 | 0.83 | NPY4R (0.47) | NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226539-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226539-B2 | Selective delivery molecules and methods of use | SLC2A8, CD44, SLC2A3 | SIRT5 4749/4885NPY4R 836/4885NPY5R 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.